Yousef Zakharia, MD, clinical associate professor of internal medicine at the University of Iowa Holden Comprehensive Cancer Center, discusses completing a recent phase 1 trial studying seleno-L-methionine (SLM) in combination with axitinib in patients with previously treated or recurring clear cell renal cell carcinoma (ccRCC). Upon finding patients with increased blood concentration of selenium had a better response, Dr. Zakharia states the protocol was amended for patients to be dosed based on their body surface area. Looking to the future, Dr. Zakharia expects a randomized clinical trial for SLM plus axitinib versus axitinib standard of care alone.

Learn more by clicking here.